Method for improving blood fat and FMD by combining qi-tonifying dripping pills containing radix astragali and radix salviae miltiorrhizae with atorvastatin and application of qi-tonifying dripping pills containing radix astragali and radix salviae miltiorrhizae
Through the combined treatment of Qishen Yiqi Drip Pills and atorvastatin, the side effects of statins alone were solved, which significantly improved the blood lipid and vascular endothelial function of patients with hyperlipidemia, delayed atherosclerosis, and reduced the heart The risk of vascular events provides a safe and effective treatment plan.
Patent Information
- Application Number
- CN202411100832.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-26
AI Technical Summary
Use of statins alone can easily lead to side effects such as drug muscle toxicity, liver damage, adverse nervous system reactions, new tumors and diabetes in the treatment of patients with hyperlipidemia, and it is difficult to effectively improve vascular endothelial function.
Using Qishen Yiqidie Pills combined with atorvastatin, patients with hyperlipidemia were subjected to continuous medication for 8-9 weeks to observe and detect blood lipid levels and brachial artery endothelial blood flow-mediated diastolic Functional, document drug-related adverse reactions, and statistical analysis was performed using SPSS and GraphPad Prism software to evaluate the safety and effectiveness of this combination therapy regimen.
Qishen Yiqidie Pills combined with atorvastatin can better regulate the blood lipid levels of patients with hyperlipidemia, protect vascular endothelial function, delay the progression of atherosclerosis, reduce the risk of cardiovascular events, and provide a safe and effective Treatment plans are worthy of clinical promotion and application.
Smart Images

Figure CN119028600A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and specifically relates to a method and application of Qishen Yiqi Dropping Pill combined with atorvastatin to improve blood lipids and FMD. Background Art
[0002] Hyperlipidemia is caused by abnormal metabolism or operation of body fat, which cannot be broken down normally, resulting in plasma lipid levels exceeding the normal range. Abnormal lipid metabolism causes lipids in the blood to accumulate in the blood vessel walls and narrow the lumen, which is an important prerequisite for the formation of atherosclerosis. Lowering blood lipids can effectively prevent the occurrence of coronary heart disease and cardiovascular emergencies. Statins are currently the first choice for the clinical treatment of hyperlipidemia. They have good therapeutic effects in lowering lipids, improving atherosclerosis, and preventing cardiovascular events. However, in recent years, concerns and debates about statins' muscle toxicity, liver damage, adverse reactions to the nervous system, new tumors, and diabetes have never stopped.
[0003] After years of clinical and scientific research practice, it was found that traditional Chinese medicine has a certain effect in regulating blood lipids and protecting endothelial function. The combined use of traditional Chinese medicine and atorvastatin has a synergistic effect, which can better lower blood lipids and improve endothelial function than atorvastatin alone. Qishen Yiqi Dropping Pills are a Chinese patent medicine composed of astragalus, salvia miltiorrhiza, Panax notoginseng, and agarwood. Clinical studies have shown that Qishen Yiqi Dropping Pills are beneficial to the long-term prognosis of patients with cardiovascular diseases. Pharmacological studies have shown that Qishen Yiqi Dropping Pills can inhibit the occurrence and development of atherosclerosis from multiple pathways. Animal experiments have shown that Qishen Yiqi Dropping Pills have a certain protective effect on the endothelial function of rats with hyperlipidemia. Other studies have shown that Qishen Yiqi Dropping Pills can significantly improve the clinical symptoms of patients with hyperlipidemia of qi deficiency and blood stasis type after 8 weeks of treatment, and lower blood lipids.
[0004] Based on the above research foundation, we conducted a clinical study on the effects of Qishen Yiqi Drops combined with atorvastatin on blood lipids and vascular endothelial function in patients with hyperlipidemia, and compared them with atorvastatin alone and Qishen Yiqi Drops alone, in order to provide a reference for optimizing clinical treatment. Summary of the invention
[0005] In view of the deficiencies in the prior art, the present invention provides a method and application of Qishen Yiqi Drop Pills combined with atorvastatin to improve blood lipids and FMD, which solves the problem that the use of statins alone in the treatment of patients easily leads to drug muscle toxicity, liver damage, adverse reactions of the nervous system, new tumors and diabetes.
[0006] To achieve the above objectives, the present invention is implemented through the following technical scheme: a method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin, comprising the following steps:
[0007] S1. Selection of experimental subjects: 122-130 patients with hyperlipidemia were selected and randomly divided into three groups, 40-42 cases in group A, 40-43 cases in group B, and 42-45 cases in group C. One-way analysis of variance and Fisher's exact test were used to compare the differences in basic demographic data among the groups;
[0008] S2. Inclusion and exclusion criteria: Use inclusion and exclusion criteria to identify patients who meet the criteria and exclude patients who do not meet the criteria to ensure the safety of the experiment;
[0009] S3. Intervention measures: Group A, Group B, and Group C were assigned different medication intervention plans, and each group took medication for 8 to 9 weeks;
[0010] S4. Observation indicators and detection methods: observe and detect the patient's blood lipid level and brachial artery endothelial blood flow-mediated diastolic function;
[0011] S401. Blood lipid level: before the experiment, when the patient is enrolled, 2-3 weeks after administration, 4-5 weeks after administration, and 8-9 weeks after administration, according to the blood lipid test regulations;
[0012] S402. Brachial artery endothelial flow-mediated vasodilation: Color Doppler ultrasound was used to detect brachial artery endothelial flow-mediated vasodilation before the experiment, at 2-3 weeks, 4-5 weeks, and 8-9 weeks of drug administration;
[0013] s5. Record safety information: Record drug-related adverse reactions during treatment;
[0014] S6. Statistical analysis: Data analysis was performed using SPSS and GraphPad Prism software, and two-way repeated measures analysis of variance was used to determine the effects of different treatments on the index values of the research subjects over time.
[0015] Preferably, the exclusion criteria mentioned in step S2 are: severe liver and kidney dysfunction, autoimmune diseases, malignant tumors, other diseases, and allergic constitution.
[0016] Preferably, the exclusion criteria mentioned in step S2 are: severe liver and kidney dysfunction, autoimmune diseases, malignant tumors, other diseases, and allergic constitution.
[0017] Preferably, the medication intervention plan for Group A mentioned in step S3 is specifically as follows: Group A is given Qishen Yiqi Dropping Pills, 0.5-0.6 g each time, 3-4 times a day, half an hour after a meal.
[0018] Preferably, the medication intervention plan for Group B mentioned in step S3 is specifically: Group B is given Qishen Yiqi Drops + Atorvastatin, with the same usage and dosage as before, and each group takes the medication continuously for 8-9 weeks.
[0019] Preferably, the medication intervention plan for Group C mentioned in step S3 is specifically as follows: Group C is given atorvastatin, 20-22 mg each time, 1-2 times a day, orally before bedtime.
[0020] Preferably, the blood lipid detection regulations mentioned in step S401 are specifically performed as follows: 5-6 ml of venous blood is drawn from the patient, centrifuged at 4°C and 3000 r / min for 10-15 min, serum is separated and collected, and stored at -80°C to 90°C for later use.
[0021] Preferably, the color Doppler ultrasound instrument mentioned in step S402 is specifically: color ultrasound instrument model: Mindray Resona 7, with a probe frequency of 5 to 14 MHz.
[0022] Preferably, the color Doppler ultrasound detection method mentioned in step S402 is specifically as follows: the patient takes a supine position, completely exposes the right upper limb, measures the distance between the anterior and posterior intimal membranes of the brachial artery at the end of vasodilation, and determines two brachial artery inner diameter values, namely the basal value and reactive hyperemia, respectively, FMD=(D1-D0) / D0×100%.
[0023] A Qishen Yiqi Drop Pill combined with atorvastatin for improving blood lipids and FMD is used in clinical medicine, cardiovascular disease management and preventive medicine.
[0024] The present invention provides a method and application of Qishen Yiqi Drop Pills combined with atorvastatin to improve blood lipids and FMD. It has the following beneficial effects:
[0025] 1. The present invention shows through research that Qishen Yiqi Drop Pills combined with atorvastatin can better regulate blood lipids (reduce TC, LDL-C) in patients with hyperlipidemia and protect endothelial function (increase FMD), thereby delaying the progression of atherosclerosis and reducing the risk of cardiovascular events, which is beneficial to the long-term prognosis of patients. It is a safe and effective treatment plan and is worthy of targeted promotion and application. The treatment time should be at least 4 weeks, preferably 8 weeks. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 is a flow chart of the present invention;
[0027] Figure 2 This is a schematic diagram of the FMD of each component at a time point of the present invention;
[0028] Figure 3 This is a schematic diagram of the time points TC of each component of the present invention;
[0029] Figure 4 This is a schematic diagram of the TG time points of each component of the present invention;
[0030] Figure 5 This is a schematic diagram of HDL-C at each component time point of the present invention;
[0031] Figure 6 Schematic diagram of LDL-C at each component time point of the present invention. DETAILED DESCRIPTION
[0032] The following will be combined with the drawings in the specification of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] Embodiment 1:
[0034] Please see attached Figure 1 - Attachment Figure 6 The embodiment of the present invention provides a method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin, comprising the following steps:
[0035] S1. Selection of experimental subjects: 122 patients with hyperlipidemia were selected and randomly divided into three groups, 40 cases in group A, 40 cases in group B, and 42 cases in group C. One-way analysis of variance and Fisher's exact test were used to compare the differences in basic demographic data among the groups. There was no statistically significant difference in general data (gender, age and basal blood lipid level) among the groups (P>0.05), and the baseline was comparable.
[0036] S2. Inclusion and exclusion criteria: determine patients who meet the criteria and exclude patients who do not meet the criteria to ensure the safety of the experiment;
[0037] Inclusion criteria: Meet the diagnostic criteria for hyperlipidemia in the "Expert Consensus on the Diagnosis and Treatment of Dyslipidemia with Integrated Traditional Chinese and Western Medicine", be diagnosed with hyperlipidemia, and be diagnosed with Qi deficiency and blood stasis type according to TCM syndrome differentiation; age 20-80 years old; have no contraindications to the drugs used in this study; have good compliance and can cooperate to complete the study; sign the informed consent form;
[0038] Exclusion criteria: severe liver and kidney dysfunction; autoimmune diseases, malignant tumors and other diseases; allergic constitution;
[0039] S3. Intervention measures: Group C was given atorvastatin, 20 mg each time, once a day, orally before bedtime; Group A was given Qishen Yiqi Dropping Pills, 0.5 g each time, 3 times a day, half an hour after meals; Group B was given Qishen Yiqi Dropping Pills + atorvastatin, with the same dosage as before, and each group was treated with medication for 8 consecutive weeks;
[0040] S4. Observation indicators and detection methods: observe and detect the patient's blood lipid level and brachial artery endothelial flow-mediated dilation (FMD) respectively;
[0041] S401. Blood lipid level: 5 ml of venous blood was drawn from patients before the experiment, when patients were enrolled, 2 weeks after administration, 4 weeks after administration, and 8 weeks after administration. The blood was centrifuged at 3000 r / min at 4°C for 10 min, and the serum was separated and collected and stored at -80°C for later use.
[0042] Automatic biochemical analyzer was used to measure blood lipid levels (TC, TG, HDL, LDL). Instrument manufacturer: Shenzhen Mindray, model: BS-420. The detection reagents were biochemical kits provided by Shenzhen Mindray. The operation was strictly in accordance with the instructions.
[0043] S402. Flow-mediated dilation (FMD) of brachial artery endothelium: Color Doppler ultrasound was used to detect the flow-mediated dilation (FMD) of brachial artery endothelium before the experiment, at the time of admission, 2 weeks, 4 weeks and 8 weeks of drug administration.
[0044] Color Doppler ultrasound model: Mindray Resona 7, probe frequency of 5-14MHz, patients were placed in supine position with right upper limb fully exposed, the distance between the anterior and posterior intimal membranes of the brachial artery was measured at the end of vasodilation, and two brachial artery inner diameter values, basal value (D0) and reactive hyperemia (D1), were determined, FMD = (D1-D0) / D0×100%.
[0045] Reactive hyperemia was induced by the following method: a blood pressure cuff was placed 2-3 cm below the elbow joint of the forearm, inflated to a sphygmomanometer reading of 200 mmHg for 5 min, and then the blood pressure cuff was suddenly relaxed to increase blood flow (i.e., reactive hyperemia). The brachial artery internal diameter after reactive hyperemia was measured 60 s after deflation.
[0046] s5. Record safety information: Record drug-related adverse reactions during treatment;
[0047] S6. Statistical analysis: Data analysis was performed using SPSS (24.0) and GraphPad Prism (9.0) software, and two-way repeated measures analysis of variance was used to determine the effects of different treatment methods on the index values of the research subjects over time (P < 0.05 was considered statistically significant).
[0048] A Qishen Yiqi Drop Pill combined with atorvastatin for improving blood lipids and FMD is used in clinical medicine, cardiovascular disease management and preventive medicine.
[0049] Effect of Example 1: Qishen Yiqi Dropping Pills combined with atorvastatin can better regulate blood lipids (reduce TC, LDL-C) and protect endothelial function (increase FMD) in patients with hyperlipidemia, thereby delaying the progression of atherosclerosis and reducing the risk of cardiovascular events.
[0050] Embodiment 2: Based on Embodiment 1, the contents of step S1 and step S3 are modified as follows:
[0051] S1. Selection of experimental subjects: 150 patients with hyperlipidemia were selected and randomly divided into three groups, 50 cases in group A, 50 cases in group B, and 50 cases in group C. Other conditions remained unchanged;
[0052] S3. Intervention measures: Group A: Qishen Yiqi Dropping Pills, 0.6 g each time, 3 times a day, half an hour after meal; Group B: Qishen Yiqi Dropping Pills (0.6 g each time, 3 times a day) + atorvastatin (25 mg each time, once a day, orally before bedtime); Group C: atorvastatin, 25 mg each time, once a day, orally before bedtime; each group took the medicine continuously for 10 weeks.
[0053] Effect of Example 2: This Example 2 may lead to more significant improvements in blood lipid levels and FMD by increasing the dose of Qishen Yiqi Drop Pills and the dose of atorvastatin and prolonging the treatment time. A longer treatment period is also helpful in evaluating long-term safety and drug tolerance.
[0054] Embodiment 3: Based on Embodiment 1, the contents of steps S4 and S6 are modified as follows:
[0055] S4. Observation indicators and detection methods:
[0056] Blood lipid level: Add an additional testing time point, that is, conduct an additional blood lipid level test at 6 weeks of administration;
[0057] FMD test: In addition to the original time points, a new FMD test at 6 weeks of administration was added, using the same equipment and methods;
[0058] S6. Statistical analysis: New time points were added during the analysis and multi-factor repeated measures ANOVA was used.
[0059] Effect of Example 3: By adding additional observation time points in the middle stage of treatment, Example 3 can more finely monitor the changing trend of the efficacy, thereby providing data support for adjusting the treatment plan or early prediction of treatment results. This method may reveal important biomarker changes in the middle stage and provide a basis for personalized medicine.
[0060] Experimental data conclusion:
[0061] FMD
[0062] The results of the variance homogeneity test showed P = 0.225. The results of the sphericity test were P = 0.417, and the data met the sphericity assumption. The results of the within-subject effect test showed that the FMD values of each group increased significantly over time after treatment (P < 0.001), and the effects of different treatments on the indicator variables and the time interaction were statistically different (P < 0.05). The results of the between-subject effect test showed P < 0.05, indicating that different treatments had significant differences in the effects of increasing FMD values. The difference between group A and group B was statistically significant (P = 0.040) when the groups were compared pairwise.
[0063] Comparison of different time points between groups: At 2 weeks of treatment, there was no statistical difference between the groups. At 4 weeks of treatment, there was a statistical difference between test group B and test group A. At 8 weeks of treatment, there was a statistical difference between test group A and control group C, between test group B and control group C, and between test group A and test group B.
[0064] FMD of each group before and after treatment
[0065]
[0066]
[0067] TC
[0068] The results of the variance homogeneity test showed that P = 0.004. The results of the sphericity test were P < 0.05, and the data did not meet the spherical hypothesis. The results of the multivariate test showed that the TC values of each group decreased significantly over time after treatment (P < 0.001), and the effects of different treatments on TC and time interaction were statistically different (P < 0.05). The results of the inter-subject effect test showed that P < 0.05, indicating that different treatments had significant differences in reducing TC values. The difference between group A and group B was statistically significant (P = 0.029) when the groups were compared pairwise.
[0069] Comparison of different time points between groups: At 2 weeks of treatment, there was a statistical difference between test group B and test group A. At 4 weeks of treatment, there was a statistical difference between test group B and test group A, and there was a statistical difference between test group B and control group C. At 8 weeks of treatment, there was a statistical difference between test group A and control group C, there was a statistical difference between test group B and control group C, and there was also a statistical difference between test group A and test group B.
[0070] TC of each group before and after treatment
[0071]
[0072]
[0073] TG
[0074] The results of the variance homogeneity test showed P = 0.421. The results of the sphericity test were P < 0.05, and the data did not meet the spherical hypothesis. The results of the multivariate test showed that the TG values of each group decreased significantly over time after treatment (P < 0.001), but there was no statistical difference in the effect of different treatment methods on the change of TG values over time (P = 0.553). The results of the inter-subject effect test showed P = 0.889, indicating that there was no significant difference in the effect of different treatment methods on reducing TG.
[0075] Comparison among the groups at different time points: There was no statistical difference among the groups at 2, 4, and 8 weeks of treatment.
[0076] TG of each group before and after treatment
[0077]
[0078] HDL-C
[0079] The results of the variance homogeneity test showed that P = 0.103. The results of the sphericity test showed that P = 0.067 > 0.05. The results of the intra-subject effect test showed that the HDL-C values of each group increased significantly over time after treatment (P < 0.001), and the effects of different treatments on HDL-C and time interaction were statistically significant (P < 0.001). The results of the inter-subject effect test showed that = 0.200, indicating that there was no significant difference in the effects of different treatments on increasing HDL-C values.
[0080] Comparison of different time points between groups: There was no statistical difference between the groups at 2 weeks of treatment. At 4 weeks of treatment, there was a statistical difference between the experimental group B and the control group C. At 8 weeks of treatment, there was a statistical difference between the experimental group B and the control group C.
[0081] HDL-C in each group before and after treatment
[0082]
[0083] LDL-C
[0084] The results of the variance homogeneity test showed P = 0.01. The results of the sphericity test were P < 0.05, and the data did not meet the spherical hypothesis. The multivariate test showed that the LDL-C values of each group decreased significantly over time after treatment (P < 0.001), and the effects of different treatments on LDL-C and time interaction were statistically different (P < 0.001). The results of the inter-subject effect test showed P < 0.05, indicating that different treatments had significant differences in reducing LDL-C values. The difference between group A and group B was statistically significant (P = 0.032) when the groups were compared pairwise.
[0085] Comparison of different time points between groups: At 2 weeks of treatment, there was no statistical difference between the groups. At 4 weeks of treatment, there was a statistical difference between test group B and test group A, and there was a statistical difference between test group B and control group C. At 8 weeks of treatment, there was a statistical difference between test group A and control group C, there was a statistical difference between test group B and control group C, and there was also a statistical difference between test group A and test group B.
[0086] LDL-C before and after treatment in each group
[0087]
[0088] Experimental conclusion:
[0089] Cardiovascular disease is one of the major diseases faced by my country and even the world, and the number of patients ranks first among internal medicine diseases. Endothelial cells are a group of cells covering the vascular endothelium, which play a barrier role between the vascular wall and the blood. Endothelial damage is the initiating factor of atherosclerosis. Many factors can cause endothelial damage, such as hyperlipidemia, hypertension, hyperglycemia, high homocysteine, high uric acid, smoking, etc. Studies have shown that oxidative stress and endothelial dysfunction caused by abnormal lipid metabolism are closely related to the occurrence of cardiovascular disease. Disorders in lipid metabolism can lead to the occurrence of oxidative stress in the body. Excessive reactive oxygen species (ROS) in the body cannot be eliminated, causing low-density lipoprotein in the body to be oxidized and modified by ROS in the arterial wall to form oxidized low-density lipoprotein (ox-LDL), causing endothelial damage, resulting in the disappearance of the endothelial cell barrier, and inflammatory factors entering the subendothelium, participating in the formation and rupture of plaques. At the same time, endothelial cells can also be stimulated by ox-LDL to become foam cells, thereby aggravating endothelial damage.
[0090] Endothelial dysfunction (ED) is a key early event in the development of atherosclerosis and an important risk factor for future cardiovascular events. The brachial artery is endothelial-dependent, and FMD is considered to be the current "gold index" for non-invasive evaluation of endothelial function. Many studies have shown that FMD in patients with coronary heart disease is abnormal and negatively correlated with the degree of coronary endothelial dysfunction. FMD can not only predict the long-term prognosis of patients with coronary heart disease, but also predict the probability of future cardiovascular disease events in healthy people. Other studies have shown that hyperlipidemia is an important factor causing endothelial dysfunction to worsen. FMD can be used to conduct an early and objective evaluation of patients' endothelial function, which has important clinical value.
[0091] This study showed that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively increase FMD in patients with hyperlipidemia. The effects of different treatments on FMD will change over time. Overall, there are significant differences in the three treatments in increasing FMD: the combined medication group is better than the Qishen Yiqi Dropping Pills group. The comparison between the groups at different time points showed that at 4 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group. At 8 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group, the combined medication group was better than the atorvastatin group, and the atorvastatin group was better than the Qishen Yiqi Dropping Pills group. This shows that Qishen Yiqi Dropping Pills combined with atorvastatin can significantly increase FMD and improve vascular endothelial dysfunction caused by hyperlipidemia. The effect is better than Qishen Yiqi Dropping Pills alone. The difference was seen at 4 weeks of treatment, and the efficacy advantage was more obvious at 8 weeks of treatment.
[0092] This study showed that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively reduce TC in patients with hyperlipidemia. The effects of different treatments on TC will change over time. Overall, there are significant differences in the three treatments in reducing TC: the combined medication group is better than the Qishen Yiqi Dropping Pills group. The comparison between the groups at different time points showed that at 2 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group. At 4 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group, and the combined medication group was better than the atorvastatin group. At 8 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group, the combined medication group was better than the atorvastatin group, and the atorvastatin group was better than the Qishen Yiqi Dropping Pills group. This shows that Qishen Yiqi Dropping Pills combined with atorvastatin can significantly reduce TC in patients with hyperlipidemia, and the effect is better than Qishen Yiqi Dropping Pills alone. The difference was reflected in 2 weeks of treatment, and the efficacy advantage was further obvious at 4 and 8 weeks of treatment.
[0093] This study showed that Qishen Yiqi Drops, atorvastatin, and Qishen Yiqi Drops combined with atorvastatin can all effectively reduce TG in patients with hyperlipidemia, but there is no significant difference among the three treatments, indicating that combined medication has no obvious advantage in lowering TG.
[0094] This study shows that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively reduce LDL-C in patients with hyperlipidemia. The effects of different treatments on LDL-C will change over time. Overall, there are significant differences in the three treatments in reducing LDL-C: the combined medication group is better than the Qishen Yiqi Dropping Pills group. The comparison between the groups at different time points showed that at 4 weeks of treatment, the combined medication group was better than the Qishen Yiqi Dropping Pills group, and the combined medication group was better than the atorvastatin group. At 8 weeks of treatment, the combined medication group was better than the atorvastatin group, the combined medication group was better than the Qishen Yiqi Dropping Pills group, and the atorvastatin group was better than the Qishen Yiqi Dropping Pills group. This shows that Qishen Yiqi Dropping Pills combined with atorvastatin can significantly reduce LDL-C in patients with hyperlipidemia, and the effect is better than Qishen Yiqi Dropping Pills alone. The difference is reflected in 4 weeks of treatment, and the efficacy advantage is more obvious at 8 weeks of treatment.
[0095] This study shows that the three treatments of Qishen Yiqi Dropping Pills, atorvastatin, and Qishen Yiqi Dropping Pills combined with atorvastatin can effectively increase the HDL-C of patients with hyperlipidemia. The effects of different treatments on HDL-C will change over time. Overall, there is no significant difference in the three treatments in increasing HDL-C. Comparison between the groups at different time points showed that at 4 weeks of treatment, the combination group was better than the atorvastatin group. At 8 weeks of treatment, the combination group was better than the atorvastatin group. This shows that Qishen Yiqi Dropping Pills combined with atorvastatin can increase HDL-C, and the effect may be better than atorvastatin alone. The difference is reflected in 4 weeks of treatment, and the efficacy advantage is more obvious at 8 weeks of treatment.
[0096] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin, characterized in that: The following steps are involved: S1. Selection of experimental subjects: 122-130 patients with hyperlipidemia were selected and randomly divided into three groups, 40-42 cases in group A, 40-43 cases in group B, and 42-45 cases in group C. One-way analysis of variance and Fisher's exact test were used to compare the differences in basic demographic data among the groups; S2. Inclusion and exclusion criteria: Use inclusion and exclusion criteria to identify patients who meet the criteria and exclude patients who do not meet the criteria to ensure the safety of the experiment; S3. Intervention measures: Group A, Group B, and Group C were assigned different medication intervention plans, and each group took medication for 8 to 9 weeks; S4. Observation indicators and detection methods: observe and detect the patient's blood lipid level and brachial artery endothelial blood flow-mediated diastolic function; S401. Blood lipid level: before the experiment, when the patient is enrolled, 2-3 weeks after administration, 4-5 weeks after administration, and 8-9 weeks after administration, according to the blood lipid test regulations; S402. Brachial artery endothelial flow-mediated vasodilation: Color Doppler ultrasound was used to detect brachial artery endothelial flow-mediated vasodilation before the experiment, at 2-3 weeks, 4-5 weeks, and 8-9 weeks of drug administration; s5. Record safety information: Record drug-related adverse reactions during treatment; S6. Statistical analysis: Data analysis was performed using SPSS and GraphPad Prism software, and two-way repeated measures analysis of variance was used to determine the effects of different treatments on the index values of the research subjects over time.
2. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The inclusion criteria mentioned in step S2 are as follows: meeting the diagnostic criteria for hyperlipidemia, being diagnosed with hyperlipidemia, and belonging to the Qi deficiency and blood stasis type according to TCM syndrome differentiation; age 20-80 years old; having no contraindications to the drugs used in this study; having good compliance and being able to cooperate in completing the study; and signing an informed consent form.
3. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The exclusion criteria mentioned in step S2 are specifically: severe liver and kidney dysfunction, autoimmune diseases, malignant tumors, other diseases, and allergic constitution.
4. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The specific medication intervention plan for Group A mentioned in step S3 is: Group A is given Qishen Yiqi Drop Pills, 0.5-0.6g each time, 3-4 times a day, half an hour after a meal.
5. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The specific medication intervention plan for Group B mentioned in step S3 is: Group B is given Qishen Yiqi Drops + Atorvastatin, with the same usage and dosage as before, and each group takes the medication continuously for 8-9 weeks.
6. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The specific medication intervention plan for Group C mentioned in step S3 is: Group C is given atorvastatin, 20-22 mg each time, 1-2 times a day, orally before bedtime.
7. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The blood lipid test mentioned in step S401 is specifically performed as follows: 5-6 ml of venous blood is drawn from the patient, centrifuged at 4°C and 3000 r / min for 10-15 min, serum is separated and collected, and stored at -80°C to 90°C for later use.
8. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The color Doppler ultrasound instrument mentioned in step S402 is specifically: color ultrasound instrument model: Mindray Resona7, probe frequency is 5-14MHz.
9. The method for improving blood lipids and FMD by combining Qishen Yiqi Drop Pills with atorvastatin according to claim 1, characterized in that: The color Doppler ultrasound detection method mentioned in step S402 is specifically as follows: the patient lies in a supine position, completely exposing the right upper limb, measuring the distance between the anterior and posterior intimal membranes of the brachial artery at the end of vasodilation, and determining two brachial artery inner diameter values, namely the basal value and reactive hyperemia, respectively, FMD=(D1-D0) / D0×100%.
10. A method for improving blood lipids and FMD by combining the Qishen Yiqi dripping pills according to any one of claims 1 to 9 with atorvastatin for use in the fields of clinical medicine, cardiovascular disease management and preventive medicine.
